1. Patients aged 18 years or above of either gender <br/ >2. Confirmed SARS-CoV-2 (COVID-19) infection by RT-PCR with PaO2:FIO2 ratio of less than 200 on admission <br/ >3. Use of one of the following for hypoxia: <br/ >a. Oxygen supplementation with an oxygen flow of at least 10 L/min independent of delivery system <br/ >b. Non-invasive ventilation or HFNC OR <br/ >c. Invasive mechanical ventilation <br/ >4. Within 48 hrs of initiation of standard therapy if <br/ >a. PaO2:FIO2 ratio worsens by more than 50 from baseline value and <br/ >b. Oxygenation or ventilation device is upgraded and <br/ >c. Increasing or static CRP <br/ >5. Imaging with chest X-ray/CT-Chest suggestive of COVID 19 related lung opacities. <br/ >6. Signature of informed consent by the patient, family member or legal representative <br/ >

1. Patients aged 18 years or above of either gender <br/ >2. Confirmed SARS-CoV-2 (COVID-19) infection by RT-PCR with PaO2:FIO2 ratio of less than 200 on admission <br/ >3. Use of one of the following for hypoxia: <br/ >a. Oxygen supplementation with an oxygen flow of at least 10 L/min independent of delivery system <br/ >b. Non-invasive ventilation or HFNC OR <br/ >c. Invasive mechanical ventilation <br/ >4. Within 48 hrs of initiation of standard therapy if <br/ >a. PaO2:FIO2 ratio worsens by more than 50 from baseline value and <br/ >b. Oxygenation or ventilation device is upgraded and <br/ >c. Increasing or static CRP <br/ >5. Imaging with chest X-ray/CT-Chest suggestive of COVID 19 related lung opacities. <br/ >6. Signature of informed consent by the patient, family member or legal representative <br/ >

1. Patients aged 18 years or above of either gender <br/ >2. Confirmed SARS-CoV-2 (COVID-19) infection by RT-PCR with PaO2:FIO2 ratio of less than 200 on admission <br/ >3. Use of one of the following for hypoxia: <br/ >a. Oxygen supplementation with an oxygen flow of at least 10 L/min independent of delivery system <br/ >b. Non-invasive ventilation or HFNC OR <br/ >c. Invasive mechanical ventilation <br/ >4. Within 48 hrs of initiation of standard therapy if <br/ >a. PaO2:FIO2 ratio worsens by more than 50 from baseline value and <br/ >b. Oxygenation or ventilation device is upgraded and <br/ >c. Increasing or static CRP <br/ >5. Imaging with chest X-ray/CT-Chest suggestive of COVID 19 related lung opacities. <br/ >6. Signature of informed consent by the patient, family member or legal representative <br/ >

1. Patients aged 18 years or above of either gender <br/ >2. Confirmed SARS-CoV-2 (COVID-19) infection by RT-PCR with PaO2:FIO2 ratio of less than 200 on admission <br/ >3. Use of one of the following for hypoxia: <br/ >a. Oxygen supplementation with an oxygen flow of at least 10 L/min independent of delivery system <br/ >b. Non-invasive ventilation or HFNC OR <br/ >c. Invasive mechanical ventilation <br/ >4. Within 48 hrs of initiation of standard therapy if <br/ >a. PaO2:FIO2 ratio worsens by more than 50 from baseline value and <br/ >b. Oxygenation or ventilation device is upgraded and <br/ >c. Increasing or static CRP <br/ >5. Imaging with chest X-ray/CT-Chest suggestive of COVID 19 related lung opacities. <br/ >6. Signature of informed consent by the patient, family member or legal representative <br/ >